Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
16-30 of 4332 results
Syndax, Nektar Therapeutics announce immuno-oncology clinical trial collaboration
Syndax Pharmaceuticals and Nektar Therapeutics have entered into a non-exclusive immuno-oncology clinical trial collaboration.
Contract Research & Services > Clinical Trials > News
Trial to test cancer combo in adults and children with leukaemia
The Combinations Alliance, a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network based at University of Birmingham, has launched a clinical trial testing a new treatment combination in patients with leukaemia.
Contract Research & Services > Clinical Trials > News
Madrigal’s liver drug succeeds in phase 2 clinical trial
By PBR Staff Writer
Madrigal Pharmaceuticals has said that its MGL-3196 thyroid hormone receptor (THR) β-selective agonist achieved liver biopsy endpoints in patients with non-alcoholic steatohepatitis (NASH) at 36 weeks in phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Janssen begins phase 1b/2 clinical trial to assess multiple myeloma treatment
Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend’s LCAR-B38M), a chimeric antigen receptor T cell (CAR-T) therapy directed against B cell maturation antigen (BCMA), in patients with relapsed or refractory multiple myeloma.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Fasenra fails in second phase III COPD trial
AstraZeneca’s Fasenra (benralizumab) failed to meet its objective in TERRANOVA, the second of two pivotal phase III trials of the drug in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Roche’s Tecentriq-chemo combo extends survival in phase 3 NSCLC trial
By PBR Staff Writer
Roche said that its cancer immunotherapy Tecentriq (atezolizumab) in combination with chemotherapy as first-line of treatment improved survival of patients with advanced non-squamous non-small cell lung cancer (NSCLC) in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
OliX secures CTA in UK to start phase I study with OLX10010
OliX Pharmaceuticals has received the phase I clinical trial authorization (CTA) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its anti-scar drug, OLX10010.
Contract Research & Services > Clinical Trials > News
ImmuPharma’s further phase III Lupuzor trial analysis shows positive results in Europe cohort
By PBR Staff Writer
ImmuPharma said that additional analysis from its phase III trial of Lupuzor in patients with systemic Lupus erythematosus (SLE) has demonstrated positive results in the Europe cohort.
Contract Research & Services > Clinical Trials > News
Midatech begins US clinical trial of MTX110 to treat DIPG
Midatech Pharma has commenced dosing in its first-in-human study with MTX110 for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive form of childhood brain cancer.
Contract Research & Services > Clinical Trials > News
Janssen to halt studies of daratumumab in combination with anti-PD-(L)1
By PBR Staff Writer
Genmab announced that Janssen will discontinue the phase Ib/II study of daratumumab in combination with atezolizumab against atezolizumab monotherapy in patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Imfinzi extends survival rate in lung cancer patients
By PBR Staff Writer
AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Midatech begins dosing in first human trial of cancer drug Q-Octreotide
Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.
Contract Research & Services > Clinical Trials > News
Janssen's Erleada shown to reduce PSA progression by 94% in nmCRPC patients
By PBR Staff Writer
Janssen Pharmaceutical's androgen receptor inhibitor Erleada (apalutamide) succeeded in a phase 3 trial by significantly cutting down the risk of prostate specific antigen (PSA) progression in patients having non-metastatic castration-resistant prostate cancer (nmCRPC).
Contract Research & Services > Clinical Trials > News
Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial
Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
Contract Research & Services > Clinical Trials > News
IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib
Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.
Contract Research & Services > Clinical Trials > News
16-30 of 4332 results